Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 329-335

  Walter, Thomas ^a,b   Horgan, Anne M ^a,c   McNamara, Mairead ^a   McKeever, Liz ^a   Min, Trisha ^a   Hedley, David ^a   Serra, Stefano ^d   Krzyzanowska, Monika K ^a   Chen, Eric ^a   MacKay, Helen ^a   Feld, Ronald ^a   Moore, Malcolm ^a   Knox, Jennifer J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c WATERFORD REGIONAL HOSPITAL   (Ireland)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Biliary tract cancer; Chemotherapy; Cholangiocarcinoma; Gallbladder; Second line

Indexed keywords

CAPECITABINE; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGE; ARTICLE; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; FEASIBILITY STUDY; FEMALE; GALLBLADDER; HUMAN; LIVER HILUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SECOND LINE CANCER CHEMOTHERAPY; SEX DIFFERENCE; VATER PAPILLA;

ADULT; AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84872117234     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.003     Document Type: Article

References (32)

1. P.C. de Groen, G.J. Gores, and N.F. LaRusso Biliary tract cancers N Engl J Med 341 1999 1368 1378
2. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, and A. Trotti III Perihilar bile ducts AJCC cancer staging handbook 7th ed. 2010 Springer Chicago, IL 718
3. A. Jemal, R. Siegel, and J. Xu Cancer statistics CA Cancer J Clin 60 2010 277 300
4. C.D. Anderson, C.W. Pinson, and J. Berlin Diagnosis and treatment of cholangiocarcinoma Oncologist 9 2004 43 57
5. A. Sharma, A.D. Dwary, and B.K. Mohanti Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study J Clin Oncol 28 2010 4581 4586
6. B. Glimelius, K. Hoffman, and P.O. Sjoden Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 1996 593 600
7. J. Valle, H. Wasan, and D.H. Palmer Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281
8. D. Malka, T. Trarbach, and L. Fartoux A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial J Clin Oncol 27 2009 (Suppl.; Abstr. 4520)
9. P.A. Cassier, C. Thevenet, and T. Walter Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma Eur J Gastroenterol Hepatol 22 2010 1111 1117
10. T. Sasaki, H. Isayama, and Y. Nakai Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer Invest New Drugs 29 2011 1488 1493
11. T. Sasaki, H. Isayama, and Y. Nakai Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine Invest New Drugs 30 2012 708 713
12. S.Y. Oh, C.Y. Jeong, and S.C. Hong Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness Invest New Drugs 29 2011 1066 1072
13. J. Stemmler, V. Heinemann, and A. Schalhorn Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases Onkologie 25 2002 182 184
14. J.J. Knox, D. Hedley, and A. Oza Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial J Clin Oncol 23 2005 2332 2338
15. R.P. Riechelmann, C.A. Townsley, and S.N. Chin Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer Cancer 110 2007 1307 1312
16. T. Andre, J.M. Reyes-Vidal, and L. Fartoux Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study Br J Cancer 99 2008 862 867
17. T. Andre, C. Tournigand, and O. Rosmorduc Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Ann Oncol 15 2004 1339 1343
18. S. Iqbal, C. Rankin, and H.J. Lenz A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202 Cancer Chemother Pharmacol 68 2011 1595 1602
19. F. Eckel, and R.M. Schmid Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 96 2007 896 902
20. S.R. Alberts, H. Al-Khatib, and M.R. Mahoney Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial Cancer 103 2005 111 118
21. J.Y. Cho, Y.H. Paik, and Y.S. Chang Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma Cancer 104 2005 2753 2758
22. J.O. Gallardo, B. Rubio, and M. Fodor A phase II study of gemcitabine in gallbladder carcinoma Ann Oncol 12 2001 1403 1406
23. R.V. Iyer, J. Gibbs, and B. Kuvshinoff A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study Ann Surg Oncol 14 2007 3202 3209
24. S. Thongprasert, S. Napapan, and C. Charoentum Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma Ann Oncol 16 2005 279 281
25. F. Verderame, A. Russo, and R. Di Leo Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers Ann Oncol 17 Suppl. 7 2006 vii68 72
26. U. Pelzer, I. Schwaner, and J. Stieler Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group Eur J Cancer 47 2011 1676 1681
27. S. Lee, S.Y. Oh, and B.G. Kim Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer Am J Clin Oncol 32 2009 348 352
28. A. Roth, E. Schleyer, and K. Schoppmeyer Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study Onkologie 34 2011 469 470
29. U. Pelzer, K. Kubica, and J. Stieler A randomized trial in patients with gemcitabine refractory pancreatic cancer. Filan results of the CONKO003 J Clin Oncol 26 2008 (Suppl.; Abstr. 4508)
30. R. Buzzoni, S. Pusceddu, and M. Platania Efficacy and safety of RAD001 I advanced biliary tract cancer patients progressing after first-line chemotherapy: a phase II study J Clin Oncol 28 2010 (Suppl.; Abstr. e14500)
31. T. Bekaii-Saab, M.A. Phelps, and X. Li Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers J Clin Oncol 29 2011 2357 2363
32. S.J. Lubner, M.R. Mahoney, and J.L. Kolesar Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study J Clin Oncol 28 2010 3491 3497